靶向p53信号通路。
Targeting the p53 pathway.
作者信息
Golubovskaya Vita M, Cance William G
机构信息
Department of Surgical Oncology, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14127, USA; CureFAKtor Pharmaceuticals, 14 Rock Dove Lane, Orchard Park, Buffalo, NY 1427, USA.
出版信息
Surg Oncol Clin N Am. 2013 Oct;22(4):747-64. doi: 10.1016/j.soc.2013.06.003. Epub 2013 Jul 30.
Abstract
This article summarizes data on translational studies to target the p53 pathway in cancer. It describes the functions of the p53 and Mdm-2 signaling pathways, and discusses current therapeutic approaches to target p53 pathways, including reactivation of p53. In addition, direct interaction and colocalization of the p53 and focal adhesion kinase proteins in cancer cells have been demonstrated, and different approaches to target this interaction are reviewed. This is a broad review of p53 function as it relates to the diagnosis and treatment of a wide range of cancers.
摘要
本文总结了针对癌症中p53通路的转化研究数据。它描述了p53和Mdm-2信号通路的功能，并讨论了目前针对p53通路的治疗方法，包括p53的重新激活。此外，已经证明了癌细胞中p53与粘着斑激酶蛋白的直接相互作用和共定位，并综述了针对这种相互作用的不同方法。这是一篇关于p53功能的广泛综述，涉及多种癌症的诊断和治疗。
相似文献
1
Targeting the p53 pathway.靶向p53信号通路。
Surg Oncol Clin N Am. 2013 Oct;22(4):747-64. doi: 10.1016/j.soc.2013.06.003. Epub 2013 Jul 30.
2
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.抑癌基因 p53：生物学、信号通路和治疗靶点。
Biochim Biophys Acta Rev Cancer. 2021 Aug;1876(1):188556. doi: 10.1016/j.bbcan.2021.188556. Epub 2021 Apr 29.
3
Small molecule agents targeting the p53-MDM2 pathway for cancer therapy.针对癌症治疗的 p53-MDM2 通路的小分子药物。
Med Res Rev. 2012 Nov;32(6):1159-96. doi: 10.1002/med.20236. Epub 2011 Jan 16.
4
In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide.一种工程化环肽激活肿瘤抑制因子 p53 通路。
J Am Chem Soc. 2013 Aug 7;135(31):11623-11633. doi: 10.1021/ja405108p. Epub 2013 Jul 25.
5
Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.分子通路：癌症治疗中的 Mdm2 和 Mdm4 靶向治疗。
Clin Cancer Res. 2013 Jan 1;19(1):34-41. doi: 10.1158/1078-0432.CCR-12-0053. Epub 2012 Dec 21.
6
Direct interaction of the N-terminal domain of focal adhesion kinase with the N-terminal transactivation domain of p53.粘着斑激酶的N端结构域与p53的N端反式激活结构域的直接相互作用。
J Biol Chem. 2005 Jul 1;280(26):25008-21. doi: 10.1074/jbc.M414172200. Epub 2005 Apr 25.
7
Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach.通过抑制 Mdm2 E3 连接酶来重新激活 p53：一种新的抗肿瘤方法。
Curr Cancer Drug Targets. 2011 Oct;11(8):987-94. doi: 10.2174/156800911797264789.
8
Pharmacological reactivation of p53 as a strategy to treat cancer.作为治疗癌症的策略，药理学激活 p53。
J Intern Med. 2015 Feb;277(2):248-259. doi: 10.1111/joim.12336.
9
Drugging the p53 pathway: understanding the route to clinical efficacy.靶向 p53 通路：探索通往临床疗效的途径。
Nat Rev Drug Discov. 2014 Mar;13(3):217-36. doi: 10.1038/nrd4236.
10
p53 Targeting can enhance cancer therapy via radiation, heat and anti-cancer agents.靶向p53可通过辐射、热疗和抗癌药物增强癌症治疗效果。
Anticancer Agents Med Chem. 2008 Jun;8(5):564-70. doi: 10.2174/187152008784533017.
引用本文的文献
1
NLRC4, inflammation and colorectal cancer (Review).NLRC4、炎症与结直肠癌（综述）。
Int J Oncol. 2024 Oct;65(4). doi: 10.3892/ijo.2024.5687. Epub 2024 Sep 6.
2
A reanalysis and integration of transcriptomics and proteomics datasets unveil novel drug targets for Mekong schistosomiasis.重新分析和整合转录组学和蛋白质组学数据集，揭示湄公血吸虫病的新药物靶点。
Sci Rep. 2024 Jun 5;14(1):12969. doi: 10.1038/s41598-024-63869-0.
3
Protective Effect of the Polysaccharides from Leaf by Modulating the p53 Signaling Pathway in H22 Tumor-Bearing Mice.叶多糖通过调节H22荷瘤小鼠p53信号通路的保护作用
Foods. 2022 Oct 24;11(21):3340. doi: 10.3390/foods11213340.
4
Post-Translational Modifications of p53 in Ferroptosis: Novel Pharmacological Targets for Cancer Therapy.铁死亡中p53的翻译后修饰：癌症治疗的新型药理学靶点
Front Pharmacol. 2022 May 24;13:908772. doi: 10.3389/fphar.2022.908772. eCollection 2022.
5
Identifying the Effect of Ursolic Acid Against Triple-Negative Breast Cancer: Coupling Network Pharmacology With Experiments Verification.鉴定熊果酸对三阴性乳腺癌的作用：网络药理学与实验验证相结合
Front Pharmacol. 2021 Nov 11;12:685773. doi: 10.3389/fphar.2021.685773. eCollection 2021.
6
Prediction of the mechanism of miRNAs in laryngeal squamous cell carcinoma based on the miRNA-mRNA regulatory network.基于miRNA-mRNA调控网络预测miRNA在喉鳞状细胞癌中的作用机制
PeerJ. 2021 Aug 24;9:e12075. doi: 10.7717/peerj.12075. eCollection 2021.
7
Recent Advances in Signaling Pathways Comprehension as Carcinogenesis Triggers in Basal Cell Carcinoma.作为基底细胞癌致癌触发因素的信号通路理解方面的最新进展
J Clin Med. 2020 Sep 18;9(9):3010. doi: 10.3390/jcm9093010.
8
Sex differences in cancer mechanisms.癌症机制中的性别差异。
Biol Sex Differ. 2020 Apr 15;11(1):17. doi: 10.1186/s13293-020-00291-x.
9
The p53 inactivators pifithrin-μ and pifithrin-α mitigate TBI-induced neuronal damage through regulation of oxidative stress, neuroinflammation, autophagy and mitophagy.p53 失活剂 pifithrin-μ 和 pifithrin-α 通过调节氧化应激、神经炎症、自噬和线粒体自噬减轻 TBI 诱导的神经元损伤。
Exp Neurol. 2020 Feb;324:113135. doi: 10.1016/j.expneurol.2019.113135. Epub 2019 Nov 26.
10
Arg72Pro polymorphism is associated with increased overall survival but not response to therapy in Portuguese/Caucasian patients with advanced cervical cancer.在患有晚期宫颈癌的葡萄牙/高加索患者中，Arg72Pro多态性与总体生存率的提高相关，但与治疗反应无关。
Oncol Lett. 2018 May;15(5):8165-8171. doi: 10.3892/ol.2018.8354. Epub 2018 Mar 26.
本文引用的文献
1
In oral squamous cell carcinoma, high FAK expression is correlated with low P53 expression.在口腔鳞状细胞癌中，高 FAK 表达与低 P53 表达相关。
Virchows Arch. 2012 Aug;461(2):163-8. doi: 10.1007/s00428-012-1283-2. Epub 2012 Jul 12.
2
Allele-specific p53 mutant reactivation.等位基因特异性 p53 突变体的重新激活。
Cancer Cell. 2012 May 15;21(5):614-625. doi: 10.1016/j.ccr.2012.03.042.
3
Nanog increases focal adhesion kinase (FAK) promoter activity and expression and directly binds to FAK protein to be phosphorylated.Nanog 可增加黏着斑激酶 (FAK) 启动子活性和表达，并直接结合到 FAK 蛋白上使其磷酸化。
J Biol Chem. 2012 May 25;287(22):18656-73. doi: 10.1074/jbc.M111.322883. Epub 2012 Apr 5.
4
A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo.一种小分子黏着斑激酶（FAK）抑制剂，靶向 Y397 位点：1-(2-羟乙基)-3,5,7-三氮杂-1-氮三环[3.3.1.1(3,7)]癸烷；溴化物能有效抑制 FAK 的自身磷酸化活性，并降低体内癌细胞的活力、集落形成能力和肿瘤生长。
Carcinogenesis. 2012 May;33(5):1004-13. doi: 10.1093/carcin/bgs120. Epub 2012 Mar 7.
5
A small-molecule inhibitor, 5'-O-tritylthymidine, targets FAK and Mdm-2 interaction, and blocks breast and colon tumorigenesis in vivo.一种小分子抑制剂，5'-O-三苯甲基胸苷，靶向 FAK 和 Mdm-2 相互作用，并阻断体内乳腺癌和结肠癌的发生。
Anticancer Agents Med Chem. 2013 May;13(4):532-45. doi: 10.2174/1871520611313040002.
6
Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma.通过 JNK 通路靶向 p53：RITA 在多发性骨髓瘤中凋亡信号的新作用。
PLoS One. 2012;7(1):e30215. doi: 10.1371/journal.pone.0030215. Epub 2012 Jan 20.
7
Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.基于小分子 p53 激活的协同生长抑制作用治疗眼内黑色素瘤。
Oncogene. 2012 Mar 1;31(9):1105-16. doi: 10.1038/onc.2011.309. Epub 2011 Jul 18.
8
RITA enhances chemosensivity of pre-B ALL cells to doxorubicin by inducing p53-dependent apoptosis.RITA通过诱导p53依赖的凋亡增强前B细胞急性淋巴细胞白血病细胞对阿霉素的化学敏感性。
Hematology. 2011 Jul;16(4):225-31. doi: 10.1179/102453311X12953015767536.
9
Translational approaches targeting the p53 pathway for anti-cancer therapy.针对 p53 通路的癌症治疗转化方法。
Br J Pharmacol. 2012 Jan;165(2):328-44. doi: 10.1111/j.1476-5381.2011.01570.x.
10
MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer.MDM2 拮抗剂增强雄激素剥夺治疗的抗肿瘤效果：对前列腺癌治疗的启示。
Mol Cancer. 2011 May 3;10:49. doi: 10.1186/1476-4598-10-49.
Zotero 插件